Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)

open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib. For all options the treatment duration is for a minimum of 12 months and will be

  • 11 views
  • 23 Feb, 2022
  • 16 locations
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim

remission
dexamethasone
vincristine
ponatinib
philadelphia chromosome
  • 87 views
  • 07 Oct, 2022
  • 88 locations
  • 2 views
  • 11 Oct, 2022
  • 64 locations
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid

t315i mutation
cns tumor
alopecia
blast crisis
leukemia
  • 34 views
  • 22 Oct, 2022
  • 11 locations
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic

  • 0 views
  • 23 Mar, 2022
  • 20 locations
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

This phase II trial studies how well low-intensity chemotherapy and ponatinib work in treating patients with Philadelphia chromosome-positive and/or BCR-ABL positive acute lymphoblastic leukemia

filgrastim
serum lipase
serum bilirubin level
leukemia
cyclophosphamide
  • 13 views
  • 28 Oct, 2022
  • 1 location
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

This is a randomised, open-label, multicenter, phase III study for adult de novo Ph+ ALL patients based on the combination of Ponatinib with Blinatumomab. The control arm will be represented by

  • 0 views
  • 24 Mar, 2022
  • 15 locations
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL (Pona-CELL)

This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic

  • 0 views
  • 04 Oct, 2022
  • 6 locations
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (TIPI)

The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a

hydroxyurea
leukemia
nilotinib
imatinib
anagrelide
  • 0 views
  • 18 Feb, 2022
  • 28 locations
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment

potassium
remission
ponatinib
kinase inhibitor
leukemia
  • 2 views
  • 14 Feb, 2022
  • 6 locations